Sanofi, Boehringer Ingelheim Corporation Forge Biologics Pact
Ingelheim, Germany - 15 January 2015 - Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies. Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.
Under the terms of the agreement Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply. Initial product transfers will begin in early 2015.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 20 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.